Auxiliary Screening COVID-19 by Serology

Pan, Xiongfeng; Kaminga, Atipatsa Chiwanda; Chen, Yuyao; Liu, Hongying; Wen, Shi Wu; Fang, Yingjing; Jia, Peng; Liu, Aizhong

doi:10.3389/fpubh.2022.819841

Cited by 3 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study the sensitivity of the rapid assays in symptomatic patients increased from 56% in the first week to 92% after 3 weeks and then decreased to 80% after >29days [105] . Pan and co-workers pooled serological data from 35775 participants from all the continents finding a good predictive value for SARS-CoV-2 infection, however data from POCs were not specifically analyzed [106] . Key considerations for evaluation of studies on LFIA have been formulated by Ochola and co-workers [80] .…”

Section: Performance and Reliability Of Lfia In Post-infectionmentioning

confidence: 99%

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

<abstract> <p>Over the last three years, after the outbreak of the COVID-19 pandemic, an unprecedented number of novel diagnostic tests have been developed. Assays to evaluate the immune response to SARS-CoV-2 have been widely considered as part of the control strategy. The lateral flow immunoassay (LFIA), to detect both IgM and IgG against SARS-CoV-2, has been widely studied as a point-of-care (POC) test. Compared to laboratory tests, LFIAs are faster, cheaper and user-friendly, thus available also in areas with low economic resources. Soon after the onset of the pandemic, numerous kits for rapid antibody detection were put on the market with an emergency use authorization. However, since then, scientists have tried to better define the accuracy of these tests and their usefulness in different contexts. In fact, while during the first phase of the pandemic LFIAs for antibody detection were auxiliary to molecular tests for the diagnosis of COVID-19, successively these tests became a tool of seroprevalence surveillance to address infection control policies. When in 2021 a massive vaccination campaign was implemented worldwide, the interest in LFIA reemerged due to the need to establish the extent and the longevity of immunization in the vaccinated population and to establish priorities to guide health policies in low-income countries with limited access to vaccines. Here, we summarize the accuracy, the advantages and limits of LFIAs as POC tests for antibody detection, highlighting the efforts that have been made to improve this technology over the last few years.</p> </abstract>

show abstract

Section: Performance and Reliability Of Lfia In Post-infectionmentioning

confidence: 99%

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

show abstract

“…5 Due to emerging new viral variants with the potential to evade the immune response, there is a continuous public health need for serological testing as an auxiliary method to screen for SARS-CoV-2 immunity in the general population. 6 Serum antibodies are detected in clinical laboratories either using an enzyme-linked immunosorbent assay (ELISA) or a chemiluminescence immunoassay (CLIA). 7 In an ELISA, the antigen of interest, protein or peptide, is attached to a microtiter plate and used to detect antibodies in the samples that would bind to the antigen.…”

Section: ■ Introductionmentioning

confidence: 99%

“…Early in the pandemic, detection of SARS-CoV_2 antibodies helped to contain and manage the pandemic by detecting people who have immunity against the virus . Due to emerging new viral variants with the potential to evade the immune response, there is a continuous public health need for serological testing as an auxiliary method to screen for SARS-CoV-2 immunity in the general population …”

Section: Introductionmentioning

confidence: 99%

Fusing Peptide Epitopes for Advanced Multiplex Serological Testing for SARS-CoV-2 Antibody Detection

Aldoukhi,

Bilalis,

Alhattab

et al. 2023

ACS Bio Med Chem Au

View full text Add to dashboard Cite

The tragic COVID-19 pandemic, which has seen a total of 655 million cases worldwide and a death toll of over 6.6 million seems finally tailing off. Even so, new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise, the severity of which cannot be predicted in advance. This is concerning for the maintenance and stability of public health, since immune evasion and increased transmissibility may arise. Therefore, it is crucial to continue monitoring antibody responses to SARS-CoV-2 in the general population. As a complement to polymerase chain reaction tests, multiplex immunoassays are elegant tools that use individual protein or peptide antigens simultaneously to provide a high level of sensitivity and specificity. To further improve these aspects of SARS-CoV-2 antibody detection, as well as accuracy, we have developed an advanced serological peptide-based multiplex assay using antigen-fused peptide epitopes derived from both the spike and the nucleocapsid proteins. The significance of the epitopes selected for antibody detection has been verified by in silico molecular docking simulations between the peptide epitopes and reported SARS-CoV-2 antibodies. Peptides can be more easily and quickly modified and synthesized than full length proteins and can, therefore, be used in a more cost-effective manner. Three different fusion-epitope peptides (FEPs) were synthesized and tested by enzyme-linked immunosorbent assay (ELISA). A total of 145 blood serum samples were used, compromising 110 COVID-19 serum samples from COVID-19 patients and 35 negative control serum samples taken from COVID-19-free individuals before the outbreak. Interestingly, our data demonstrate that the sensitivity, specificity, and accuracy of the results for the FEP antigens are higher than for single peptide epitopes or mixtures of single peptide epitopes. Our FEP concept can be applied to different multiplex immunoassays testing not only for SARS-CoV-2 but also for various other pathogens. A significantly improved peptide-based serological assay may support the development of commercial point-of-care tests, such as lateral-flow-assays.

show abstract

Sensitive detection of SARS-CoV-2 spike protein based on electrochemical impedance spectroscopy of Fe3O4@SiO2–Au/GCE biosensor

You

Liu

et al. 2023

Advanced Sensor and Energy Materials

View full text Add to dashboard Cite

Auxiliary Screening COVID-19 by Serology

Cited by 3 publications

References 38 publications

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Fusing Peptide Epitopes for Advanced Multiplex Serological Testing for SARS-CoV-2 Antibody Detection

Sensitive detection of SARS-CoV-2 spike protein based on electrochemical impedance spectroscopy of Fe3O4@SiO2–Au/GCE biosensor

Contact Info

Product

Resources

About